Compare GIII & CMPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GIII | CMPS |
|---|---|---|
| Founded | 1956 | 2020 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Apparel | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.2B |
| IPO Year | 2006 | 2020 |
| Metric | GIII | CMPS |
|---|---|---|
| Price | $34.11 | $13.05 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 8 |
| Target Price | ★ $29.00 | $25.38 |
| AVG Volume (30 Days) | 606.9K | ★ 4.0M |
| Earning Date | 06-05-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.29% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.50 | N/A |
| Revenue | ★ $2,957,012,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $22.90 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $22.92 | $3.50 |
| 52 Week High | $36.53 | $15.40 |
| Indicator | GIII | CMPS |
|---|---|---|
| Relative Strength Index (RSI) | 54.02 | 52.31 |
| Support Level | $31.83 | $5.57 |
| Resistance Level | $34.83 | $15.08 |
| Average True Range (ATR) | 1.01 | 1.07 |
| MACD | -0.05 | -0.13 |
| Stochastic Oscillator | 63.39 | 40.36 |
G-III Apparel Group Ltd is an apparel manufacturing company. The company makes a wide range of apparel, footwear, and accessories that sells under its own brands, licensed brands, and private-label brands. It has a substantial portfolio for licensed and proprietary brands, anchored by brands: DKNY, Donna Karan, Karl Lagerfeld, Karl Lagerfeld Paris, Vilebrequin, and others. The reportable segments of the company are Wholesale Operations and Retail Operations. The Wholesale operations segment includes sales of products under brands licensed by from third parties, and sales of products under its own brands and private label brands. The retail operations segment consists of Wilsons Leather, G.H. Bass, and DKNY retail stores. It derives majority of its revenue from Wholesale operations.
Compass Pathways PLC is a biotechnology company focused on developing therapies for mental health conditions. Its research centers on a proprietary synthetic psilocybin formulation, COMP360, which is administered alongside psychological support. The company is conducting clinical trials to evaluate the safety and efficacy of this treatment in patients with treatment-resistant depression and other mental health disorders. The company operates in one operating segment.